Maraviroc acts as:
Maraviroc binds specifically and selectively to CCR5, one of two coreceptors necessary for entrance of HIV into CD4+ cells, thus blocking entry of CCR5-tropic HIV into these cells. Ref: Katzung 11th edition Chapter 49.
Reverse transcriptase inhibitor
Protease inhibitor
Entry inhibitor
None of the above